Quick Facts: Therapeutic Domains

• Hormone Support: May be used to support the uterus lining in post-menopausal women with an intact uterus who are receiving estrogen-based Hormone Replacement Therapy (HRT).
• Reproductive Care: May be indicated to support the luteal phase during Assisted Reproductive Technology (ART) cycles.
• Obstetrics: May be utilized for the prevention of preterm birth in certain women with a singleton pregnancy and specific risk factors.

---

What Utrogestan treats: main uses and benefits

Utrogestan is a treatment option primarily indicated for conditions associated with an insufficient amount of a naturally occurring hormone. The medication is used as a component of Hormone Replacement Therapy (HRT). In postmenopausal women who still have their uterus and are receiving estrogen, this treatment may help to prevent the excessive thickening of the endometrium, which may be associated with estrogen-only therapy. This supports the maintenance of a healthy uterine lining.

The medication is also utilized in reproductive care to support the luteal phase of the menstrual cycle in women undergoing Assisted Reproductive Technology (ART) cycles. Furthermore, Utrogestan may be prescribed to certain women with a singleton pregnancy for the prevention of preterm birth, particularly those identified with a short cervix or a history of spontaneous preterm birth. All therapeutic uses are determined based on an individual's specific clinical presentation and requirements.

Eligibility to Use Utrogestan

Utrogestan (micronised progesterone) is typically prescribed to women who still have a womb (uterus) as a component of Hormone Replacement Therapy (HRT) to protect the womb lining from the effects of estrogen. It is not suitable for women who have had a hysterectomy for this indication.

Contraindications (Must Not Use)

Official regulatory documents state that this medicine is contraindicated and must not be used by individuals with certain serious medical conditions, including:

• Known, past, or suspected cancers of the breast or genital tract.
• Severe liver disease or liver function tests that have not returned to normal.
• Active or previous blood clots (venous or arterial thromboembolism) or known thrombophilic disorders.
• Undiagnosed abnormal vaginal bleeding.
• Hypersensitivity (allergy) to progesterone, soya, or peanut.

Use Requires Special Consideration

Use of Utrogestan requires close medical supervision and is not recommended in patients with conditions that can be aggravated by fluid retention (e.g., severe hypertension, heart or kidney disease, asthma, epilepsy), a history of depression, or conditions like severe migraines and diabetes mellitus. Use in pregnancy and lactation is generally restricted or avoided, with specific allowances only for certain, time-limited treatment protocols during the first trimester.

Utrogestan Interactions with other medicines and products

Interactions involving Utrogestan (micronised progesterone) are primarily determined by its metabolism in the liver. Concomitant use with medicines that affect the activity of liver enzymes may alter the concentration of progesterone in the body.

Documented Interacting Categories

• Enzyme Inducers: Medicines that accelerate progesterone's breakdown, potentially reducing its effectiveness. This group includes certain anticonvulsants (e.g., phenobarbital, phenytoin, carbamazepine), rifamycin medicines (e.g., rifampicin), and some antibiotics (e.g., ampicillins, tetracyclines). The herbal supplement St. John's wort is also known to have an enzyme-inducing effect.
• Enzyme Inhibitors: Agents that slow the breakdown of progesterone, which may increase its levels. The antifungal medicine ketoconazole is an example.
• Other Medications: Progesterone may affect the plasma concentration of other drugs, such as the immunosuppressant ciclosporin, or interfere with the effects of bromocriptine.

Administration Constraints

• Food Interaction: When taken orally, Utrogestan capsules must be taken without food, typically at bedtime. Concomitant food intake is known to increase progesterone absorption and bioavailability.
• Vaginal Use: When using the vaginal capsule, it should not be used with other vaginal preparations (e.g., antifungal products) as this may interfere with the intended release and absorption of progesterone.

How Utrogestan Works: Mechanism of Action

Utrogestan (micronized progesterone) acts by agonizing the nuclear Progesterone Receptor (PR), modulating gene transcription to exert systemic physiological effects. Its mechanism operates across two primary domains: peripheral reproductive tissue control and central nervous system modulation.

---

Hormone Receptor Agonism and Endometrial Transformation

Utrogestan functions as a direct Progesterone Receptor agonist. The binding and activation of the PR lead to the genomic modulation of target genes in the endometrium. This molecular cascade initiates the shift from the proliferative phase to the secretory phase, a physiological transformation resulting in endometrial change (decidualization) or structural breakdown.

---

Uterine Relaxation and CNS Neurosteroid Modulation

Utrogestan's second domain involves two physiological outcomes: uterine relaxation and central nervous system (CNS) effects. Peripherally, the mechanism dampens the excitability of the myometrium, resulting in reduced contractions. Centrally, it is metabolized into neurosteroids like allopregnanolone, which act as positive allosteric modulators of GABAA receptors . This non-genomic action enhances inhibitory signaling, resulting in physiological effects characterized by CNS dampening and reduced neuronal activity.

Official Administration Instructions

Utrogestan (micronized progesterone) must be used strictly according to the specific regimen prescribed by a healthcare professional. The medicine is available as a capsule for use by either the oral or the vaginal route, depending on the therapeutic plan.

Key Administration Guidelines

The route of administration is either oral (swallowed whole with water) or vaginal (inserted deep into the vagina). The specific use will dictate the appropriate route.

Oral capsules must be taken on an empty stomach and should not be taken with food. To help ensure compliance and minimize certain effects, oral administration is preferably taken at bedtime.

Dosing and Scheduling

The prescribed dosing schedule is highly specific and often involves cyclical use. For example, in some regimens, the dose may be 200 mg daily for 12 days in the latter half of the cycle, or 100 mg daily administered from Day 1 to Day 25. The precise daily dosage and the duration of the cycle must be followed exactly as specified.

If a missed dose is discovered, it should be taken as soon as the individual remembers. However, if it is nearly time for the next scheduled dose, the missed dose must be skipped entirely, and the regular schedule should be resumed. Individuals must never take a double dose to make up for a skipped one.

Procedural Step	Requirement
Route of Administration	Oral or Vaginal insertion
Timing (Oral)	On an empty stomach, preferably at bedtime
Missed Dose Rule	Take immediately unless nearly time for next dose; do not double dose

These instructions define the standardized procedure for taking the medicine.

Research evidence / Overview of studies for Utrogestan

Evidence for Use in Hormone Replacement Therapy (HRT)

This section will summarize the available evidence from randomized controlled trials and systematic reviews that evaluated the preparation’s role in managing the uterine lining in post-menopausal women receiving estrogen.

Research examined the use of micronised progesterone as a component of Hormone Replacement Therapy (HRT) in post-menopausal women with an intact uterus. Researchers conducted Randomized Controlled Trials (RCTs) and Systematic Reviews to specifically evaluate outcomes related to the health of the uterine lining (endometrium). When added to estrogen therapy, research describes histological patterns observed in the studies that were consistent with the necessary change from proliferative to secretory phases in the endometrium. Studies report how this approach was associated with patterns of maintaining the uterine lining health in the observed populations.

The long-term effects are not fully established for all possible HRT regimens, particularly for certain continuous combined dose patterns. Follow-up durations were limited in some pivotal trials, though long-term observational settings were observed in some research.

---

Evidence for Use in Assisted Reproductive Technology (ART)

This section will outline the research base, including meta-analyses and controlled trials, that investigated the use of this preparation for providing luteal phase support during assisted reproductive cycles.

Studies focused on women undergoing Assisted Reproductive Technology (ART). Research examined outcomes related to providing support during the luteal phase of the cycle. The main study outcomes examined were key measurements of treatment success, including live birth rate, clinical pregnancy rate, and ongoing pregnancy rate. Studies report how, in these research scenarios, the use of progesterone for luteal support data show patterns related to pregnancy outcomes that were compared to control groups receiving no support.

Evidence quality varies across studies for this indication. Sample sizes were modest in some earlier trials included in the systematic reviews. Research exploring short-term symptom changes suggests that the evidence is generally heterogeneous due to the wide variety of study designs and protocols used.

---

Evidence for Preventing Spontaneous Preterm Birth

This section will detail the body of research, particularly high-level individual patient data (IPD) meta-analyses, that examined the preparation's utility in pregnancy for women identified with specific risk factors like a short cervix.

Studies explored whether this preparation may assist in the prevention of spontaneous preterm birth. This evaluation focused specifically on asymptomatic women with a singleton pregnancy identified with a short cervix (an anatomical risk factor). Individual Patient Data (IPD) Meta-analyses are the highest form of evidence available here. These studies data show patterns related to the incidence of spontaneous preterm birth before 33 weeks of gestation in the specific high-risk populations studied. Results apply only to the populations studied, meaning the findings are specific to women with a singleton pregnancy and a short cervix.

Few data are available to support the use of this preparation for twin or multifetal pregnancies, and data for certain groups remain insufficient.

Key Studies & References

1. Progestogens and endometrial protection - British Menopause Society (BMS) Consensus Statement
2. Recommendations | Preterm labour and birth | NICE Guideline NG25

Common questions about Utrogestan (FAQ)

---

Q: Why does Utrogestan cause drowsiness?

According to official product information, drowsiness (somnolence) is listed as a common side effect of Utrogestan. This effect is linked to how the medicine is processed in the body, creating compounds that influence the central nervous system (CNS). If taken orally, this effect is most often observed at the start of treatment or immediately following the dose.

---

Q: What is the specific role of micronisation in the Utrogestan capsule?

Utrogestan utilizes a specific manufacturing technique called micronisation. The micronised formulation is designed to reduce the particle size of the hormone. Official information indicates that this is intended to help enhance the absorption and bioavailability (how much medicine enters the body's circulation) of the active ingredient.

---

Q: Which is the better route: oral or vaginal administration?

Official labeling indicates that the choice between the oral or vaginal route depends on the specific therapeutic plan, which is determined by a healthcare professional. The product labeling indicates that certain systemic side effects, such as dizziness or drowsiness, are reported to be less frequent when the vaginal route is used at recommended doses compared to oral administration.

---

Q: What is the difference between Utrogestan and a synthetic progestin?

Utrogestan contains micronized progesterone. According to official pharmacological descriptions, this is a bio-identical hormone that is chemically and structurally identical to the progesterone naturally produced in the human body. This differentiates it from synthetic progestins, which are chemically modified versions of the hormone.

---

Q: Is Utrogestan safe to take while breastfeeding?

Regulatory information indicates that the active substance passes into breast milk in detectable amounts. Due to the transfer into breast milk, the official product labeling generally states that the medicine is not indicated or is generally avoided during the period of breastfeeding.

Utrogestan Storage and Disposal Requirements

The storage of Utrogestan soft capsules must comply with specific temperature and packaging requirements to maintain the product's stability.

Mandatory Storage Conditions

• Temperature: Store the medicine below 30 C (some regions require storage below 25 C). Do not use the product after the expiration date (EXP) marked on the packaging.
• Protection: The capsules must be kept in their original blister pack and outer carton to protect from light.
• Safety: The product must be kept out of the sight and reach of children.

Disposal Instructions

• Do not throw away unused or expired Utrogestan via wastewater or household waste.
• Disposal must be executed in accordance with local regulations as advised by a pharmacist, to ensure environmentally compliant removal of the product.